Table 3. Fold increase in anti-peptide IgG titer in subjects enrolled in 5 schedules.

Group	W-4	W-7	W-10	W-13	W-22	W-46	W-70
A	4	32	32	16	16	16	8
A	1	4	4	2	2	2	2
A	NA	NA	64	32	16	16	32
A	1	1	1	N/A	N/A	N/A	N/A
A	1	1	1	1	1	1	1
	W-7	W-10	W-13	W-16	W-22	W-46	W-70
B	1	1	1	1	1	8	8
B	1	1	1	1	4	8	8
B	4	16	16	64	32	16	N/A
B	1	1	2	2	2	1	2
B	16	32	32	32	8	4	4
	W-7	W-10	W-13	W-16	W-25	W-49	W-73
C	8	32	32	4	4	2	2
C	4	4	4	32	32	32	N/A
C	8	16	32	64	64	64	N/A
C	1	1	1	1	1	8	4
C	64	256	256	256	64	16	32
	W-5	W-8	W-11	W-14	W-23	W-47	W-71
D	1	4	4	8	N/A	8	N/A
D	1	1	1	1	1	2	2
D	8	16	16	8	8	16	N/A
D	1	1	1	1	2	2	2
D	2	1	1	2	1	1	16
	W-6	W-9	W-12	W-15	W-24	W-48	W-72
E	4	8	32	N/A	N/A	NA	N/A
E	2	4	4	8	8	16	8
E	2	8	4	N/A	N/A	N/A	N/A
E	4	4	4	N/A	N/A	N/A	N/A
E	4	2	2	N/A	N/A	N/A	N/A

Antibody titer was determined in pre-immune samples and at various times (weeks, W) after immunization. The fold increase in antibody titer (relative to pre-immune levels) is reported.